Company intelligence / Profile preview

Epalex

Not specified, California, United Statesepalex.com ↗

Ownership: Private
Employees: ~7
Development stage: Phase 2

Overview

Developing novel therapies for migraine and epilepsy with unique mechanisms of action. EP102 for migraine and EP103 for epilepsy are in development. Their proprietary delivery technology improves bioavailability by increasing peak concentration and area under the curve compared to standard tablets.

Therapeutic areas: Neurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

2 assets

propofol hemisuccinate

Preclinical

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Epalex.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Epalex.

Explore the full profile